Search

Search Constraints

You searched for: Author/Creator Foley, John

Search Results

1. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Issue 6 (24th May 2018)

2. 136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS. Issue 9 (12th August 2022)

4. Adaptation of clinical pharmacy services to meet patient care needs during the COVID‐19 pandemic. Issue 3 (28th January 2021)